Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
bivirkning af phenylpropanolaminhydrochlorid |
Causative agent |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
1 |
allergi over for phenylpropanolaminhydrochlorid |
Causative agent |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
phenylpropanolaminhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
brompheniraminmaleat + codeinphosphat + phenylpropanolaminhydrochlorid 2 mg/5 ml 10 mg/5 ml 12,5 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
brompheniraminmaleat + dextromethorphanhydrobromid + phenylpropanolaminhydrochlorid 2 mg/5 ml 10 mg/5 ml 12,5 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
brompheniraminmaleat 2 mg + dextromethorphanhydrobromid 10 mg + phenylpropanolaminhydrochlorid 12,5 mg væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
brompheniraminmaleat + codeinphosphat + phenylpropanolaminhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
brompheniraminmaleat + dextromethorphanhydrobromid + phenylpropanolaminhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely chlorphenamine maleate 4 milligram and mepyramine maleate 25 milligram and phenylephrine hydrochloride 10 milligram and phenylpropanolamine 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
|
allergi over for phenylpropanolaminhydrochlorid |
Causative agent |
False |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
1 |
Brompheniramine maleate 400 microgram/mL and codeine phosphate 2 mg/mL and phenylpropanolamine hydrochloride 2.5 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
3 |
Brompheniramine maleate 400 microgram/mL and codeine phosphate 2 mg/mL and phenylpropanolamine hydrochloride 2.5 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
3 |
Product containing precisely brompheniramine maleate 400 microgram/1 milliliter and dextromethorphan hydrobromide 2 milligram/1 milliliter and phenylpropanolamine hydrochloride 2.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
3 |
Product containing precisely brompheniramine maleate 400 microgram/1 milliliter and dextromethorphan hydrobromide 2 milligram/1 milliliter and phenylpropanolamine hydrochloride 2.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Phenylpropanolamine hydrochloride |
Inferred relationship |
Some |
3 |